- Adios to the first quarter $XBI $IBB $LABU
- Biomarin's rare disease data has a few warts $BMRN
- Valeant: fresh accusations as CEO Pearson prepares to depart $VRX
- Patent issues strike Biogen, Gilead $BIIB $GILD $MRK $IONS
- Only Portola is impressed with their phase 3 blood thinner data $PTLA
- Alder provides relief with positive migraine study data $ALDR
- Acadia wins thumbs up for psychiatric drug from FDA panel $ACAD
- As seen on the stream (the best of the rest!)
Biotech Tweets of the Week (March 21 - April 1, 2016)